ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) – Equities researchers at HC Wainwright boosted their FY2027 EPS estimates for shares of ACADIA Pharmaceuticals in a research report issued to ...
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Kamada (KMDA) or Acadia Pharmaceuticals (ACAD). But which of these two stocks is more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback